Myriad Genetics (MYGN) Competitors $14.19 -0.79 (-5.27%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$14.28 +0.08 (+0.59%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MYGN vs. IONS, FOLD, LGND, BCRX, DVAX, GERN, CLDX, MNKD, NVAX, and INVAShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Geron (GERN), Celldex Therapeutics (CLDX), MannKind (MNKD), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Ionis Pharmaceuticals Amicus Therapeutics Ligand Pharmaceuticals BioCryst Pharmaceuticals Dynavax Technologies Geron Celldex Therapeutics MannKind Novavax Innoviva Ionis Pharmaceuticals (NASDAQ:IONS) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability. Does the media favor IONS or MYGN? In the previous week, Ionis Pharmaceuticals had 24 more articles in the media than Myriad Genetics. MarketBeat recorded 30 mentions for Ionis Pharmaceuticals and 6 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.42 beat Ionis Pharmaceuticals' score of 0.25 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Neutral Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, IONS or MYGN? Ionis Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Do analysts prefer IONS or MYGN? Ionis Pharmaceuticals currently has a consensus target price of $60.00, suggesting a potential upside of 85.60%. Myriad Genetics has a consensus target price of $22.54, suggesting a potential upside of 58.82%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.70Myriad Genetics 3 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the MarketBeat Community believe in IONS or MYGN? Ionis Pharmaceuticals received 227 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 60.36% of users gave Ionis Pharmaceuticals an outperform vote while only 52.97% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformIonis PharmaceuticalsOutperform Votes69960.36% Underperform Votes45939.64% Myriad GeneticsOutperform Votes47252.97% Underperform Votes41947.03% Which has preferable earnings & valuation, IONS or MYGN? Myriad Genetics has higher revenue and earnings than Ionis Pharmaceuticals. Myriad Genetics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$705.14M7.29-$366.29M-$3.04-10.63Myriad Genetics$823.60M1.57-$263.30M-$1.30-10.92 Is IONS or MYGN more profitable? Myriad Genetics has a net margin of -14.09% compared to Ionis Pharmaceuticals' net margin of -64.25%. Myriad Genetics' return on equity of -4.51% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-64.25% -100.05% -15.70% Myriad Genetics -14.09%-4.51%-3.07% Do institutionals and insiders believe in IONS or MYGN? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryIonis Pharmaceuticals beats Myriad Genetics on 10 of the 19 factors compared between the two stocks. Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$2.60B$5.84B$9.13BDividend YieldN/A0.75%4.75%3.86%P/E Ratio-10.925.5526.8119.21Price / Sales1.5759.81428.4069.50Price / CashN/A15.7538.0134.83Price / Book1.493.287.644.62Net Income-$263.30M-$65.73M$3.19B$246.06M7 Day Performance-2.53%-4.01%-2.13%-2.63%1 Month Performance11.21%-8.51%-1.11%-2.57%1 Year Performance-37.54%-21.19%15.71%12.71% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics3.9372 of 5 stars$14.19-5.3%$22.54+58.8%-38.6%$1.29B$823.60M-10.922,700Analyst DowngradeIONSIonis Pharmaceuticals4.4172 of 5 stars$31.04+2.3%$60.65+95.4%-26.5%$4.90B$788M-12.72800Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageFOLDAmicus Therapeutics4.1796 of 5 stars$9.77+1.3%$16.88+72.7%-31.4%$2.92B$399.36M-28.74480Analyst DowngradeNews CoverageLGNDLigand Pharmaceuticals4.0554 of 5 stars$120.00+5.3%$147.00+22.5%+63.9%$2.27B$131.31M47.8180Positive NewsBCRXBioCryst Pharmaceuticals3.9161 of 5 stars$9.05+2.6%$15.50+71.3%+58.2%$1.87B$331.41M-14.84530Upcoming EarningsHigh Trading VolumeDVAXDynavax Technologies4.2605 of 5 stars$12.82+1.0%$21.50+67.7%+7.2%$1.69B$232.28M98.62350Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpGERNGeron3.0163 of 5 stars$2.56-8.2%$7.25+183.2%+30.7%$1.55B$240,000.00-8.0070Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeCLDXCelldex Therapeutics1.183 of 5 stars$22.70-1.6%$60.22+165.3%-40.0%$1.51B$6.88M-8.83150MNKDMannKind2.6798 of 5 stars$5.42-2.3%$9.21+70.0%+60.6%$1.49B$198.96M77.43400Upcoming EarningsNVAXNovavax4.0639 of 5 stars$8.19+0.1%$17.83+117.7%+63.7%$1.31B$983.71M-3.621,543Analyst RevisionNews CoverageINVAInnoviva3.1261 of 5 stars$18.08-0.8%N/A+16.8%$1.13B$310.46M26.20100Analyst DowngradeNews Coverage Related Companies and Tools Related Companies IONS Alternatives FOLD Alternatives LGND Alternatives BCRX Alternatives DVAX Alternatives GERN Alternatives CLDX Alternatives MNKD Alternatives NVAX Alternatives INVA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYGN) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
